Aarey Drugs Fined ₹5,900 Each by BSE & NSE for Delayed Related Party Transaction Disclosure
Aarey Drugs & Pharmaceuticals Limited was fined ₹5,900 each by BSE and NSE for delayed submission of related party transactions for the period ending September 30, 2025. The company has paid the fine and assured that corrective measures are in place to prevent future non-compliance.
The fines are nominal (₹5,900 per exchange) and the issue is procedural with no indication of significant financial or operational impact on the company.
The company received fines from stock exchanges for non-compliance, which is a negative event.
Aarey Drugs & Pharmaceuticals Limited has received notices from both BSE and NSE imposing a fine of ₹5,000 plus 18% GST, totaling ₹5,900 to each exchange. This penalty is for non-compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically for the delayed submission of related party transactions for the period ended September 30, 2025.
The company's Board of Directors has acknowledged these notices. They stated that the delay was inadvertent and procedural, and the required disclosure has since been submitted. The company has also paid the stipulated fines to both stock exchanges. Steps are being taken to enhance internal compliance monitoring to prevent future occurrences.
The notices also advised the company to ensure compliance and pay the fines within 15 days. Failure to do so could lead to actions such as freezing of promoter's shareholding. The company was also reminded that second consecutive year of non-compliance with Regulation 33 could result in transfer to Z group. The Board's comments on this matter are to be placed before the next board meeting and informed to the exchanges.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under related party transactions. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.